The effect of a subcutaneous infusion of GLP-1, OXM, and PYY on energy intake and expenditure in obese volunteers

Journal of Clinical Endocrinology and Metabolism

Volumn 102, Issue 7, 2017, Pages 2364-2372

  Tan, Tricia ^a   Behary, Preeshila ^a   Tharakan, George ^a   Minnion, James ^a   Al Najim, Werd ^a   Wewer Albrechtsen, Nicolai J ^b   Holst, Jens J ^b   Bloom, Stephen R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Capital Region   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; OXYNTOMODULIN; PEPTIDE YY; PLACEBO;

ADULT; AMBULATORY CARE; ARTICLE; CALORIC INTAKE; CALORIMETER; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG EFFECT; DRUG SAFETY; ENERGY EXPENDITURE; FEMALE; HORMONE ACTION; HUMAN; MALE; MIDDLE AGED; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROUX-EN-Y GASTRIC BYPASS; SINGLE BLIND PROCEDURE; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; BODY MASS; DRUG EFFECTS; ENERGY METABOLISM; FOLLOW UP; GASTRIC BYPASS SURGERY; OBESITY, MORBID; PAIN MEASUREMENT; PATIENT SAFETY; PROCEDURES; RISK ASSESSMENT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; UNITED KINGDOM; VOLUNTEER;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BODY MASS INDEX; CROSS-OVER STUDIES; ENERGY METABOLISM; FEMALE; FOLLOW-UP STUDIES; GASTRIC BYPASS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OBESITY, MORBID; OXYNTOMODULIN; PAIN MEASUREMENT; PATIENT SAFETY; PEPTIDE YY; RISK ASSESSMENT; SINGLE-BLIND METHOD; TREATMENT OUTCOME; UNITED KINGDOM; VOLUNTEERS;

EID: 85023158328     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2017-00469     Document Type: Article

References (37)

1. Public Health England. Adult obesity and type 2 diabetes. Available at: www. gov. uk/government/uploads/system/uploads/attachment-data/file/338934/Adult-obesity-and-type-2-diabetes-. pdf. Accessed 12 April 2017.
2. Ng M, Fleming T,RobinsonMTB, et al. Global, regional and national prevalence of overweight and obesity in children and adults 1980-2013: a systematic analysis. Lancet. 2014;384:766-781.
3. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, Castagneto M, Bornstein S, Rubino F. Bariatricmetabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an openlabel, single-centre, randomised controlled trial. Lancet. 2015; 386(9997):964-973.
4. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial: a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219-234.
5. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996; 379(6560):69-72.
6. Batterham RL, ffytche DH, Rosenthal JM, Zelaya FO, Barker GJ, Withers DJ, Williams SC. PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature. 2007;450(7166):106-109.
7. Wewer Albrechtsen NJ, Hornburg D, Albrechtsen R, Svendsen B, Toräng S, Jepsen SL, Kuhre RE, Hansen M, Janus C, Floyd A, Lund A, Vilsbøll T, Knop FK, Vestergaard H, Deacon CF, Meissner F, Mann M, Holst JJ, Hartmann B. Oxyntomodulin Identified as a marker of type 2 diabetes and gastric bypass surgery by massspectrometry based profiling of human plasma. EBioMedicine. 2016;7:112-120.
8. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int JObes. 2006;30(12):1729-1736.
9. Dar MS, Chapman WH III, Pender JR, Drake AJ III, O'Brien K, Tanenberg RJ, Dohm GL, Pories WJ. GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)? Obes Surg. 2012;22(7):1077-1083.
10. Falkeń Y, Hellström PM, Holst JJ, Näslund E. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96(7):2227-2235.
11. Laferrère B, Swerdlow N, Bawa B, Arias S, Bose M, Oliván B, Teixeira J, McGinty J, Rother KI. Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab. 2010;95(8):4072-4076.
12. le Roux CW, Aylwin SJB, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei MA, Patel AG, Bloom SR. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243(1):108-114.
13. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418(6898):650-654.
14. Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM, Long SJ, Morgan LM, Holst JJ, Astrup A. A metaanalysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001; 86(9):4382-4389.
15. De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA, Ghatei MA, Bloom SR, Matthews PM, Beaver JD, Dhillo WS. The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab. 2011;14(5):700-706.
16. Schmidt JB, GregersenNT, Pedersen SD,Arentoft JL, Ritz C, Schwartz TW, Holst JJ, Astrup A, Sjödin A. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. Am J Physiol Endocrinol Metab. 2014;306(11):E1248-E1256.
17. Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA, Bloom SR. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology. 2005;146(12): 5120-5127.
18. Field BCT, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, Alsaraf S, Amber V, Wynne K, Ghatei MA, Bloom SR. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes. 2010;59(7):1635-1639.
19. Cegla J, Troke RC, Jones B, et al. Co-infusion of low-dose glucagon-like peptide-1 (GLP-1) and 1 glucagon in man results in a reduction in food intake. Diabetes. 2014;44:1-28.
20. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999; 22(7):1137-1143.
21. Torekov SS, Kipnes MS, Harley RE, Holst JJ, Ehlers MR. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(7):639-643.
22. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and b-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824-830.
23. Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JMED. Effects of 3 months of continuous glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care. 2003;26:2835-2841.
24. van Strien T, Jan ER, Frijters PD, Gerard PA, Bergers MS, Defares PB. The Dutch Eating Behavior Qusetionnaires (DEBQ) for assessment of restraint, emotional, and external eating behavior. Int J Eat Disord. 1986;5:295-315.
25. Morgan JF, Reid F, Lacey JH. The SCOFF questionnaire: assessment of a new screening tool for eating disorders. BMJ. 1999; 319(7223):1467-1468.
26. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000;24(1):38-48.
27. Kraegen EW, Lazarus L, Meler H, Campbell L, Chia YO. Carrier solutions for low-level intravenous insulin infusion. BMJ. 1975; 3(5981):464-466.
28. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987; 2(8571):1300-1304.
29. Batterham RL, CohenMA, Ellis SM, Le Roux CW,Withers DJ, Frost GS, GhateiMA, BloomSR. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl JMed. 2003;349(10):941-948.
30. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, Frost GS, Ghatei MA, Bloom SR. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab. 2003;88(10):4696-4701.
31. Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, Filippaios A, Bowers J, Srnka A, Gavrieli A, Ko BJ, Liakou C, Kanyuch N, Tseleni-Balafouta S, Mantzoros CS. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016;59(5):954-965.
32. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-161.
33. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3. 0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22.
34. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245-256.
35. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9774):1341-1352.
36. Bagger JI, Holst JJ, Hartmann B, Andersen B, Knop FK, Vilsbøll T. Effect of oxyntomodulin, glucagon, GLP-1, and combined glucagon + GLP-1 infusion on food intake, appetite, and resting energy expenditure. J Clin Endocrinol Metab. 2015;100(12):4541-4552.
37. Laurenius A, Larsson I, Bueter M, Melanson KJ, Bosaeus I, Forslund HB, Lönroth H, Fändriks L, Olbers T. Changes in eating behaviour and meal pattern following Roux-en-Y gastric bypass. Int J Obes. 2012;36(3):348-355.